Inflammation News and Research

RSS

Manhattan Pharmaceuticals to merge with Ariston Pharmaceuticals

Manhattan Pharmaceuticals, Inc. today announced it has entered into a definitive agreement and plan of merger and completed the merger transaction with Ariston Pharmaceuticals, Inc., a privately-held, specialty pharmaceutical company. As a result of the merger, Ariston became a wholly owned subsidiary of Manhattan Pharmaceuticals.

12 Mar 2010

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2009.

12 Mar 2010

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063.

12 Mar 2010

Bayer HealthCare Pharmaceuticals' ciprofloxacin DPI granted FDA orphan drug designation for CF treatment

Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration for ciprofloxacin dry powder inhaler for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients. A similar designation has already been granted by the European Medicines Agency.

12 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

BioInvent International AB and Human Genome Sciences, Inc. today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.

11 Mar 2010

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Human Genome Sciences, Inc. and BioInvent International AB today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.

11 Mar 2010

Lithera announces positive results from Phase IIa clinical study of LIPO-102

Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.

11 Mar 2010

TNS acquires license to Ergothioneine Transporter from University of Cologne

Total Nutraceutical Solutions, Inc. announced that the company has acquired from the University of Cologne, Cologne, Germany, an exclusive license agreement on the invention entitled “Ergothioneine Transporter,” owned by the University.

10 Mar 2010

USA/Ireland Functional Foods conference to focus on science of gut function and response to diet

Understanding the science of how the human gut functions and the role that diet plays in human health will be explored at a major International Functional Foods conference in Cork, this week. Foods have an enormous role to play in keeping people healthy and many foods have properties that can enhance the health of those that consume them.

10 Mar 2010

Papaya's anticancer effect against broad range of lab-grown tumors documented

The humble papaya is gaining credibility in Western medicine for anticancer powers that folk cultures have recognized for generations.

10 Mar 2010

Novel interventions for New World hemorrhagic fevers needed

New World hemorrhagic fevers are emerging infectious diseases found in South America that can cause terrible, Ebola-like symptoms. Current treatments are expensive and only partially effective.

9 Mar 2010

New program specifically tailored to teens could help them manage and avoid asthma

An asthma program specifically tailored to teens could help those in rural areas manage their disease and avoid potentially fatal complications, Medical College of Georgia researchers say.

9 Mar 2010

New nutrition product to address effects of Glycation

After an extensive on going research program, Mineral BioSciences LLC a division of Global Organics Group is proud to announce the introduction of TOTALA® Nutrients, an ingredient that promises to have a profound effect on the nutrition industry.

8 Mar 2010

Scientists identify EoE-associated region in human chromosome

Scientists have identified a region of a human chromosome that is associated with eosinophilic esophagitis (EoE), a recently recognized allergic disease. People with EoE frequently have difficulty eating or may be allergic to one or more foods. This study further suggests that a suspected so-called master allergy gene may play a role in the development of this rare but debilitating disorder.

8 Mar 2010

Pediatrics researchers identify major gene location responsible for EoE

Pediatrics researchers have identified the first major gene location responsible for a severe, often painful type of food allergy called eosinophilic esophagitis (EoE). In this disease, which may cause weight loss, vomiting, heartburn and swallowing difficulties, a patient may be unable to eat a wide variety of foods.

7 Mar 2010

Electromagnetic pulses decrease pain and inflammation associated with osteoarthritis of knee

Electromagnetic pulses significantly decrease pain and inflammation associated with osteoarthritis of the knee, according to Henry Ford Hospital researchers.

7 Mar 2010

Differentiation of cirrhosis from inflammation in patients with ALD: Novel bedside criteria identified

Alcoholic liver disease (ALD) is the most common cause of liver cirrhosis in the Western world. Liver biopsy is currently considered the gold standard for assessing hepatic fibrosis or cirrhosis in these patients. However, it is an invasive procedure, with rare but potentially life-threatening complications and its accuracy is limited due to sampling error. Transient elastography (FibroScan-, FS) is a novel rapid and noninvasive method to assess liver fibrosis via measurement of liver stiffness (LS).

6 Mar 2010

People with skin of color more prone to dermatologic problems than those with lighter skin tones

According to projections from the United States Census Bureau, people with skin of color will comprise approximately half of the U.S. population by 2050. This group, which includes African-Americans, Asians, Latinos and other ethnicities, are more prone to certain dermatologic problems than those with lighter skin tones due to their genetic make-up and in some cases cultural practices.

5 Mar 2010

Worm proteins may provide option in management of gastrointestinal inflammation in IBD patients

Patients with inflammatory bowel disease (IBD) suffer from chronic inflammation of the gut leading to gastrointestinal motility alterations with symptoms such as abdominal pain, cramps and diarrhea that profoundly affect their quality of life. The lack of exposure to worm infections, as a result of improved living standards and medical conditions, might have contributed to the increased incidence of IBD in the Western world.

5 Mar 2010

Inflammation News and Research

Manhattan Pharmaceuticals to merge with Ariston Pharmaceuticals

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

Bayer HealthCare Pharmaceuticals' ciprofloxacin DPI granted FDA orphan drug designation for CF treatment

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Lithera announces positive results from Phase IIa clinical study of LIPO-102

TNS acquires license to Ergothioneine Transporter from University of Cologne

USA/Ireland Functional Foods conference to focus on science of gut function and response to diet

Papaya's anticancer effect against broad range of lab-grown tumors documented

Novel interventions for New World hemorrhagic fevers needed

New program specifically tailored to teens could help them manage and avoid asthma

New nutrition product to address effects of Glycation

Scientists identify EoE-associated region in human chromosome

Pediatrics researchers identify major gene location responsible for EoE

Electromagnetic pulses decrease pain and inflammation associated with osteoarthritis of knee

Differentiation of cirrhosis from inflammation in patients with ALD: Novel bedside criteria identified

People with skin of color more prone to dermatologic problems than those with lighter skin tones

Worm proteins may provide option in management of gastrointestinal inflammation in IBD patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News